HIND Vyome Holdings, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—
Margins
Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%
Returns
ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x
Cash quality & payout
Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $319,714 | $256,944 | $8.68M | $11.24M | $13.60M |
| Cost of revenue | $100,943 | $61,974 | $3.13M | $4.44M | $5.25M |
| Gross profit | $218,771 | $194,970 | $5.55M | $6.80M | $8.35M |
| R&D expense | $588,258 | $285,391 | $2.31M | $2.54M | $2.37M |
| SG&A expense | $2.37M | $898,572 | $10.32M | $14.09M | $8.89M |
| Operating income | -$10.45M | -$1.01M | -$15.38M | -$46.35M | -$57.88M |
| Interest expense | $146,641 | $206,004 | — | — | — |
| Pretax income | — | -$7.09M | -$11.34M | -$46.59M | -$63.42M |
| Income tax | — | $39,000 | $52,000 | -$380,000 | -$274,000 |
| Net income | -$10.26M | -$1.45M | -$11.39M | -$46.21M | -$63.15M |
| EBITDA | -$10.44M | -$988,993 | -$15.26M | -$46.02M | -$57.65M |
| EPS (basic) | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 |
| EPS (diluted) | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 |
| Weighted avg. shares (diluted) | 2.16M | 241 | 102,707 | 424,390 | 218,522 |
| Balance sheet | |||||
| Cash & equivalents | $4.98M | $101,904 | $16,647 | $3.96M | $22.82M |
| Receivables | $325 | $2,294 | $1.70M | — | — |
| Inventory | — | $2.46M | $3.74M | $3.61M | $3.00M |
| Current assets | $5.44M | $302,046 | $10.30M | $9.91M | $29.94M |
| PP&E, net | $46,393 | $59,179 | $60,000 | $698,000 | $1.45M |
| Intangibles | $314,191 | $314,191 | — | $260,000 | $13.88M |
| Total assets | $6.50M | $1.38M | $10.66M | $11.14M | $52.53M |
| Current liabilities | $2.74M | $5.74M | $3.78M | $7.48M | $7.53M |
| Short-term debt | — | $811,000 | — | — | — |
| Total liabilities | $2.74M | $5.77M | $4.00M | $7.48M | $8.20M |
| Shareholders' equity | $2.44M | -$4.39M | $6.66M | $3.66M | $44.33M |
| Shares outstanding | 5.92M | 0 | 404,437 | 519,219 | 356,641 |
| Cash flow statement | |||||
| Operating cash flow | -$3.75M | -$614,136 | -$16.96M | -$21.90M | -$15.38M |
| Capital expenditure | — | — | $43,000 | $131,000 | $352,000 |
| Free cash flow | — | — | -$17.00M | -$22.03M | -$15.73M |
| Investing cash flow | — | $315 | -$10,000 | -$92,000 | $1.85M |
| Financing cash flow | $8.65M | $697,951 | $17.57M | $3.13M | $33.30M |
| Depreciation & amortization | $11,985 | $17,347 | $121,000 | $330,000 | $232,000 |
| Stock-based compensation | $577,128 | $184,000 | $766,000 | $2.09M | $12.23M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.